Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings

Bristol-Myers Squibb yields about 4.3% and trades at 9.1x forward EV/EBIT. Read why BMY stock offers an attractive ...
Clinical Trials Arena on MSN

BMS gains two pivotal trial wins in lung disease and rare cancer

BMS will be speaking with regulatory authorities based on data from the pivotal trial of the IPF drug.
Fierce Biotech

BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth

Bristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth. | Bristol Myers Squibb has reported phase 3 wins in a ...

[BMS] Idiopathic Pulmonary Fibrosis (IPF) Treatment Admilparant Meets Primary Endpoint in Phase 3 Trial | Aiming for First-in-Class Status

Bristol Myers Squibb announced that the admilparant Phase 3 ALOFT-IPF trial in adult patients with idiopathic pulmonary ...
pharmaphorum

BMS eyes filings for idiopathic pulmonary fibrosis drug

Bristol Myers Squibb has reported phase 3 results with a new type of drug for idiopathic pulmonary fibrosis (IPF) that could ...

Why does BMS, with a 96% Copilot adoption rate, also investigate 'frequent users'?—How to interpret usage data to embed enterprise AI

After introducing generative AI to a company, it is natural to think, "Let's reduce the number of people who aren't using it." But is that alone enough?Looking at the case of the US pharmaceutical ...